Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$26.72 - $33.19 $2.66 Million - $3.31 Million
-99,700 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$24.15 - $31.45 $355,343 - $462,755
-14,714 Reduced 12.86%
99,700 $2.61 Million
Q4 2020

Feb 02, 2021

SELL
$17.7 - $25.81 $21,717 - $31,668
-1,227 Reduced 1.06%
114,414 $2.88 Million
Q3 2020

Nov 05, 2020

BUY
$20.2 - $25.05 $90,092 - $111,723
4,460 Added 4.01%
115,641 $2.41 Million
Q2 2020

Aug 12, 2020

SELL
$17.09 - $24.89 $4,135 - $6,023
-242 Reduced 0.22%
111,181 $2.64 Million
Q1 2020

May 12, 2020

SELL
$14.45 - $24.69 $606,293 - $1.04 Million
-41,958 Reduced 27.36%
111,423 $2 Million
Q4 2019

Jan 27, 2020

BUY
$19.93 - $29.13 $994,666 - $1.45 Million
49,908 Added 48.23%
153,381 $3.64 Million
Q3 2019

Oct 31, 2019

BUY
$25.47 - $33.37 $712,166 - $933,058
27,961 Added 37.03%
103,473 $2.84 Million
Q2 2019

Aug 15, 2019

SELL
$29.96 - $38.87 $101,624 - $131,847
-3,392 Reduced 4.3%
75,512 $2.5 Million
Q1 2019

May 03, 2019

BUY
$32.77 - $41.99 $109,222 - $139,952
3,333 Added 4.41%
78,904 $2.77 Million
Q4 2018

Feb 08, 2019

SELL
$30.84 - $49.51 $185,040 - $297,060
-6,000 Reduced 7.36%
75,571 $2.51 Million
Q3 2018

Nov 13, 2018

BUY
$42.7 - $56.55 $384,897 - $509,741
9,014 Added 12.42%
81,571 $4.11 Million
Q2 2018

Aug 15, 2018

BUY
$44.1 - $59.85 $903,873 - $1.23 Million
20,496 Added 39.37%
72,557 $4.34 Million
Q1 2018

May 11, 2018

SELL
$37.15 - $46.9 $264,062 - $333,365
-7,108 Reduced 12.01%
52,061 $2.38 Million
Q4 2017

Feb 06, 2018

BUY
$36.4 - $42.6 $439,675 - $514,565
12,079 Added 25.65%
59,169 $2.36 Million
Q3 2017

Nov 15, 2017

BUY
$36.75 - $49.65 $1.73 Million - $2.34 Million
47,090
47,090 $1.88 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.75B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.